OBJECTIVE: We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel. METHODS: The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) trial included 2,022 patients with non-ST elevation ACS undergoing PCI who were randomized to abciximab or placebo after pretreatment with 600 mg of clopidogrel. The patients were divided into groups with elevated TnT level (n = 1,049) and no elevated TnT level (n = 973). The primary end point of the trial was the composite of death, myocardial infarction and urgent reintervention at 30 days. RESULTS: In patients with elevated TnT level the incidence of the primary end point was 13.1% in the abciximab group Vs. 18.3% in the placebo group [relative risk (RR): 0.70; 95% confidence interval (CI), 0.52-0.95, P = 0.02]. The combined incidence of death or myocardial infarction was 12.9% in the abciximab group vs. 17.9% in the placebo group (RR: 0.71; 95% CI, 0.52-0.96, P = 0.03). In contrast, the incidence of the primary end point in patients with no elevated TnT level was identical in both treatment groups (4.6%). The risk of bleeding was not related to TnT level. CONCLUSIONS: Baseline troponin level affects the benefit of abciximab in patients with ACS undergoing PCI after pretreatment with a high loading dose of clopidogrel. Abciximab reduces the risk of ischemic events only in patients with ACS and elevated troponin level.
RCT Entities:
OBJECTIVE: We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel. METHODS: The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) trial included 2,022 patients with non-ST elevation ACS undergoing PCI who were randomized to abciximab or placebo after pretreatment with 600 mg of clopidogrel. The patients were divided into groups with elevated TnT level (n = 1,049) and no elevated TnT level (n = 973). The primary end point of the trial was the composite of death, myocardial infarction and urgent reintervention at 30 days. RESULTS: In patients with elevated TnT level the incidence of the primary end point was 13.1% in the abciximab group Vs. 18.3% in the placebo group [relative risk (RR): 0.70; 95% confidence interval (CI), 0.52-0.95, P = 0.02]. The combined incidence of death or myocardial infarction was 12.9% in the abciximab group vs. 17.9% in the placebo group (RR: 0.71; 95% CI, 0.52-0.96, P = 0.03). In contrast, the incidence of the primary end point in patients with no elevated TnT level was identical in both treatment groups (4.6%). The risk of bleeding was not related to TnT level. CONCLUSIONS: Baseline troponin level affects the benefit of abciximab in patients with ACS undergoing PCI after pretreatment with a high loading dose of clopidogrel. Abciximab reduces the risk of ischemic events only in patients with ACS and elevated troponin level.
Authors: C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245
Authors: K A Ault; C P Cannon; J Mitchell; J McCahan; R P Tracy; W F Novotny; J D Reimann; E Braunwald Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith Journal: J Am Coll Cardiol Date: 2002-10-02 Impact factor: 24.094
Authors: Albert Schömig; Claus Schmitt; Alban Dibra; Julinda Mehilli; Christian Volmer; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Peter B Berger; Adnan Kastrati Journal: Eur Heart J Date: 2005-02-25 Impact factor: 29.983
Authors: Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig Journal: JAMA Date: 2006-03-13 Impact factor: 56.272
Authors: E M Ohman; P W Armstrong; R H Christenson; C B Granger; H A Katus; C W Hamm; M A O'Hanesian; G S Wagner; N S Kleiman; F E Harrell; R M Califf; E J Topol Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: W E Boden; R A O'Rourke; M H Crawford; A S Blaustein; P C Deedwania; R G Zoble; L F Wexler; R E Kleiger; C J Pepine; D R Ferry; B K Chow; P W Lavori Journal: N Engl J Med Date: 1998-06-18 Impact factor: 91.245
Authors: Stefanie Schulz; K Anette Birkmeier; Gjin Ndrepepa; Werner Moshage; Franz Dotzer; Kurt Huber; Josef Dirschinger; Melchior Seyfarth; Albert Schömig; Adnan Kastrati; Julinda Mehilli Journal: Clin Res Cardiol Date: 2010-06-27 Impact factor: 5.460
Authors: Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A Birkmeier; Klaus Tiroch; Robert A Byrne; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2011-03-08 Impact factor: 5.460
Authors: Timm Bauer; Helge Möllmann; Franz Weidinger; Uwe Zeymer; Ricardo Seabra-Gomes; Franz Eberli; Patrick Serruys; Alec Vahanian; Sigmund Silber; William Wijns; Matthias Hochadel; Holger M Nef; Christian W Hamm; Jean Marco; Anselm K Gitt Journal: Clin Res Cardiol Date: 2010-02-26 Impact factor: 5.460
Authors: Ingo Wickenbrock; Christian Perings; Petra Maagh; Ivo Quack; Marc van Bracht; Magnus W Prull; Gunnar Plehn; Hans-Joachim Trappe; Axel Meissner Journal: Clin Res Cardiol Date: 2009-10-23 Impact factor: 5.460
Authors: Juergen Kammler; Alexander Kypta; Robert Hofmann; Klaus Kerschner; Michael Grund; Kurt Sihorsch; Clemens Steinwender; Thomas Lambert; Wolfram Helml; Franz Leisch Journal: Clin Res Cardiol Date: 2008-10-30 Impact factor: 5.460